By: 4 August 2022
TRB UK announce sales agreement with Vivostat

TRB Chemedica UK have recently announced a new and exclusive sales & marketing agreement with Danish company Vivostat®.

Vivostat A/S is a privately owned company based in Copenhagen, in the Medicon Valley of Scandinavia. Specialising in Biotechnology and Medical Engineering, they are the creators of the internationally renowned Vivostat® System.

ArthroZheal® is the latest product to incorporate use of the system, and represents an important progression in the orthopaedic surgeon’s capacity to seal, heal and regenerate compromised tissue.

The new alliance will see TRB Chemedica UK launch ArthroZheal® across the UK and Ireland. ArthroZheal® is a unique and innovative bioactive matrix, rich in platelet-derived growth factors, specifically designed for use during arthroscopic surgery. It can also be used as an injectable therapeutic, enabling topical healing and regeneration of tissue such as cartilage, tendons and ligaments.

TRB Chemedica UK Managing Director, Mr Alex Flanagan, said “ArthroZheal® is a remarkable new product, and a great addition to our portfolio. It sits very comfortably alongside our flagship OSTENIL® Range of viscosupplement injections, and our post-arthroscopic synovial fluid replacement, VISCOSEAL®. We’re looking forward to working with Vivostat®, and promoting the benefits of ArthroZheal® to the NHS and private sectors across the whole of the UK and Ireland.”

Image: From left to right: Marko Rackovic – VP Sales & Marketing (Vivostat) Alex Flanagan – Managing Director (TRB Chemedica UK) Ben Taylor Dingwall – Commercial Manager UK & IRE (TRB Chemedica UK) Jaap Suyk – Senior Business Development Manager (Vivostat)

For further information contact your local TRB Representative, or visit their website at